Entera Bio (ENTX, Financial) has shared promising outcomes from a Phase 2 study of their osteoporosis treatment, EB613, at the 2025 World Congress on Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases in Rome. The study assessed the impact of EB613 on bone health in 161 postmenopausal women who were given either a placebo or one of four doses of EB613 for six months.
The results highlighted significant improvements in various bone health metrics for those treated with EB613 compared to the placebo group. Key findings included enhancements in integral volumetric bone mineral density (BMD), trabecular volumetric BMD, cortical thickness, and cortical surface BMD. These metrics indicate a broad distribution of bone gain in the femur amongst participants receiving EB613, contrasting with the bone loss observed in the placebo group.
Looking ahead, Entera Bio plans to further explore the safety and efficacy of EB613 in a forthcoming Phase 3 trial, aiming to confirm these early findings and potentially bring a new treatment option to those suffering from low bone mass or osteoporosis.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Entera Bio Ltd (ENTX, Financial) is $10.00 with a high estimate of $10.00 and a low estimate of $10.00. The average target implies an upside of 474.71% from the current price of $1.74. More detailed estimate data can be found on the Entera Bio Ltd (ENTX) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, Entera Bio Ltd's (ENTX, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
